- Imugene (IMU) will present its immunotherapy programme at the American Association for Cancer Research’s annual meeting
- Imugene’s Chief Medical Officer is set to present at the meeting on the company’s HER-Vaxx cancer immunotherapy programme
- HER-vaxx has shown promising antibody responses against HER-2 cancer growth signals in phase one and two preclinical trials
- At this stage, the full content of the presentation is embargoed but will be made available when the presentation takes place in April
- Imugene is up 5 per cent on the market, trading at 10.5 cents per share
Imugene (IMU) will present its immunotherapy programme at the American Association for Cancer Research’s annual meeting.
Imugene’s Chief Medical Officer, Dr Rita Laeufle, is set to present at the American Association for Cancer Research’s virtual annual meeting, scheduled for April this year.
IMU says the exhibition covers its HER-Vaxx cancer immunotherapy program.
HER-Vaxx is designed to produce an antibody response against a cancer growth signal receptor protein called ‘HER-2’, which is found on the cell surface in ovarian, lung and pancreatic cancers.
The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of the HER-2/neu protein.
Pre-clinical studies in phase one and two stages have shown HER-Vaxx can stimulate a potent antibody response to HER-2/neu, a well-known cancer target.
While the full content of the presentation is embargoed until the start of the conference, it will be made available online once the meeting has started.
The American Association for Cancer Research is widely regarded as one of the largest and oldest cancer research bodies.
Imugene is up 5 per cent on the market, trading at 10.5 cents per share at 10:38 am AEDT.